Science Advances

Supplementary Materials

The PDF file includes:

  • Supplementary Materials and Methods
  • Fig. S1. Discovery of pentacyclic triterpene glycoconjugates as EBOV entry inhibitors.
  • Fig. S2. Time-of-addition experiments to clarify the stage at which lead compounds blocked EBOV entry.
  • Fig. S3. Characterization of the affinity of triterpenoid compounds to N-terminal HR1, C-terminal HR2, and their effect on HR1-HR2 interaction.
  • Fig. S4. Characterization of the spatial interactions within the triterpenoid-HR2 complex according to NMR spectra.
  • Fig. S5. Docking simulation and biological mapping supporting a structural model of the triterpenoid lead compound–HR2 complex.
  • Fig. S6. Characterization of the affinity of triterpenoid compounds Y19 and Y20 to HIV HR2 and HR1 and their effect on HR1-HR2 interactions.
  • Fig. S7. Identification of HR2 in influenza HA2 as the domain targeted by the triterpenoid leads.
  • Fig. S8. Production and characterization of the HR2 peptide (KIDQIIHDF)–specific polyclonal antibody.
  • Fig. S9. The structure-activity relationship of triterpenoids against viruses according to our study.
  • Table S1. Broad antiviral spectra of the tested compounds against various EBOV subtypes and MARV.

Download PDF

Other Supplementary Material for this manuscript includes the following:

  • Movie S1 (.avi format). The EBOV-host membrane fusion via a trimer-of-hairpins.
  • Movie S2 (.avi format). Pentacyclic triterpene lead compounds inhibit virus-host membrane fusion by targeting the HR2 of virus envelope protein.

Files in this Data Supplement: